药学学报, 2020, 55(10): 2243-2255
乔露瑶, 张晓伟. “异常肝再生”的发生机制及其在肝纤维化治疗中的作用[J]. 药学学报, 2020, 55(10): 2243-2255.
QIAO Lu-yao, ZHANG Xiao-wei. Mechanism of “aberrant liver regeneration” and its role in treatment of liver fibrosis[J]. Acta Pharmaceutica Sinica, 2020, 55(10): 2243-2255.

乔露瑶, 张晓伟
中国医学科学院、北京协和医学院药物研究所, 北京 100050
关键词:    肝再生      肝硬化      肝细胞      星形细胞     
Mechanism of “aberrant liver regeneration” and its role in treatment of liver fibrosis
QIAO Lu-yao, ZHANG Xiao-wei
Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
Liver fibrosis is a critical pathological structural basis of a variety of chronic liver diseases such as alcoholic liver disease, viral hepatitis and nodular cirrhosis, while liver regeneration is the key mechanism for protecting liver against multiple injuries, promoting inflammation resolution and reversing liver fibrosis. When fibrosis occurs after liver injuries, the alternation of liver regeneration status in fibrosis usually plays an essential role in the outcome of diverse liver diseases. In this review, the differences between "homeostatic regeneration", "normal regeneration" and "aberrant regeneration" were identified in terms of the occurrence conditions, the basic state of the liver, the effects on liver repair, the types of cells involved and the pathogenesis. Emphatically, we not only summarize the differences of mechanisms between "aberrant regeneration" and "normal regeneration" in the pathogenesis of liver fibrosis, but also elucidate the features of "aberrant regeneration" in various liver fibrosis models, as well as the therapeutic strategies for the treatment of liver fibrosis based on "aberrant regeneration", expecting to provide evidence and clues for considering the risks and proposing possible solutions in clinical treatment of liver fibrosis.
Key words:    liver regeneration    cirrhosis    hepatocyte    hepatic stellate cell   
收稿日期: 2020-03-10
DOI: 10.16438/j.0513-4870.2020-0282
基金项目: 国家自然科学基金资助项目(81773800);中国医学科学院医学与健康科技创新工程重大协同创新项目(2016-I2M-1-010).
通讯作者: 张晓伟,Tel:86-10-83161187,E-mail:zhxw@imm.ac.cn
Email: zhxw@imm.ac.cn
PDF(1927KB) Free
乔露瑶  在本刊中的所有文章
张晓伟  在本刊中的所有文章

[1] Distler JHW, Györfi AH, Ramanujam M, et al. Shared and distinct mechanisms of fibrosis[J]. Nat Rev Rheumatol, 2019, 15:705-730.
[2] Damle-Vartak A, Begher-Tibbe B, Gunther G, et al. Pipe-3d:a pipeline based on immunofluorescence, 3D confocal imaging, reconstructions, and morphometry for biliary network analysis in cholestasis[J]. Methods Mol Biol, 2019, 1981:25-53.
[3] Forbes SJ, Rosenthal N. Preparing the ground for tissue regeneration:from mechanism to therapy[J]. Nat Med, 2014, 20:857-869.
[4] Aizarani N, Saviano A, Sagar, et al. A human liver cell Atlas reveals heterogeneity and epithelial progenitors[J]. Nature, 2019, 572:199-204.
[5] Chen F, Jimenez RJ, Sharma K, et al. Broad distribution of hepatocyte proliferation in liver homeostasis and regeneration[J]. Cell Stem Cell, 2020, 26:27-33.
[6] Lin S, Nascimento EM, Gajera CR, et al. Distributed hepatocytes expressing telomerase repopulate the liver in homeostasis and injury[J]. Nature, 2018, 556:244-248.
[7] Wang B, Zhao L, Fish M, et al. Self-renewing diploid Axin2+ cells fuel homeostatic renewal of the liver[J]. Nature, 2015, 524:180-185.
[8] Sun T, Pikiolek M, Orsini V, et al. Axin2 pericentral hepatocytes have limited contributions to liver homeostasis and regeneration[J]. Cell Stem Cell, 2020, 26:97-107.
[9] Ding BS, Cao Z, Lis R, et al. Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis[J]. Nature, 2014, 505:97-102.
[10] Fazel Modares N, Polz R, Haghighi F, et al. Il-6trans-signaling controls liver regeneration after partial hepatectomy[J]. Hepatology, 2019, 70:2075-2091.
[11] Garbers C, Hermanns HM, Schaper F, et al. Plasticity and cross-talk of interleukin 6-type cytokines[J]. Cytokine Growth Factor Rev, 2012, 23:85-97.
[12] Yin C, Evason KJ, Asahina K, et al. Hepatic stellate cells in liver development, regeneration, and cancer[J]. J Clin Invest, 2013, 123:1902-1910.
[13] Hu C, Wu Z, Li L. Mesenchymal stromal cells promote liver regeneration through regulation of immune cells[J]. Int J Biol Sci, 2020, 16:893-903.
[14] Banales JM, Huebert RC, Karlsen T, et al. Cholangiocyte pathobiology[J]. Nat Rev Gastroenterol Hepatol, 2019, 16:269-281.
[15] Yanger K, Zong Y, Maggs LR, et al. Robust cellular reprogramming occurs spontaneously during liver regeneration[J]. Genes Dev, 2013, 27:719-724.
[16] Okabe H, Yang J, Sylakowski K, et al. Wnt signaling regulates hepatobiliary repair following cholestatic liver injury in mice[J]. Hepatology, 2016, 64:1652-1666.
[17] Yimlamai D, Christodoulou C, Galli GG, et al. Hippo pathway activity influences liver cell fate[J]. Cell, 2014, 157:1324-1338.
[18] Li W, Yang L, He Q, et al. A homeostatic Arid1a-dependent permissive chromatin state licenses hepatocyte responsiveness to liver-injury-associated Yap signaling[J]. Cell Stem Cell, 2019, 25:54-68.
[19] Tanimizu N, Ichinohe N, Yamamoto M, et al. Progressive induction of hepatocyte progenitor cells in chronically injured liver[J]. Sci Rep, 2017, 7:39990.
[20] Font-Burgada J, Shalapour S, Ramaswamy S, et al. Hybrid periportal hepatocytes regenerate the injured liver without giving rise to cancer[J]. Cell, 2015, 162:766-779.
[21] Miyajima A, Tanaka M, Itoh T. Stem/progenitor cells in liver development, homeostasis, regeneration, and reprogramming[J]. Cell Stem Cell, 2014, 14:561-574.
[22] Li W, Li L, Hui L. Cell plasticity in liver regeneration[J]. Trends Cell Biol, 2020, 30:329-338.
[23] Tanimizu N, Nakamura Y, Ichinohe N, et al. Hepatic biliary epithelial cells acquire epithelial integrity but lose plasticity to differentiate into hepatocytes in vitro during development[J]. J Cell Sci, 2013, 126:5239-5246.
[24] Shiojiri N, Kametani H, Ota N, et al. Phylogenetic analyses of the hepatic architecture in vertebrates[J]. J Anat, 2018, 232:200-213.
[25] Choi TY, Khaliq M, Tsurusaki S, et al. Bone morphogenetic protein signaling governs biliary-driven liver regeneration in zebrafish through Tbx2b and Id2a[J]. Hepatology, 2017, 66:1616-1630.
[26] Sauer V, Roy-Chowdhury N, Guha C, et al. Induced pluripotent stem cells as a source of hepatocytes[J]. Curr Pathobiol Rep, 2014, 2:11-20.
[27] Sun L, Wang Y, Cen J, et al. Modelling liver cancer initiation with organoids derived from directly reprogrammed human hepatocytes[J]. Nat Cell Biol, 2019, 21:1015-1026.
[28] Wu XX, Zhang CZ, Wang X, et al. Targeting angiogenesis and vascular remodeling as a novel therapeutic approach to liver fibrosis[J]. Acta Pharm Sin (药学学报), 2015, 50:535-540.
[29] Lee JS, Semela D, Iredale J, et al. Sinusoidal remodeling and angiogenesis:a new function for the liver-specific pericyte[J]. Hepatology, 2007, 45:817-825.
[30] Passino MA, Adams RA, Sikorski Sl, et al. Regulation of hepatic stellate cell differentiation by the neurotrophin receptor P75ntr[J]. Science, 2007, 315:1853-1856.
[31] Ochoa B, Syn WK, Delgado I, et al. Hedgehog signaling is critical for normal liver regeneration after partial hepatectomy in mice[J]. Hepatology, 2010, 51:1712-1723.
[32] Ebrahimkhani MR, Oakley F, Murphy LB, et al. Stimulating healthy tissue regeneration by targeting the 5-Ht2B receptor in chronic liver disease[J]. Nat Med, 2011, 17:1668-1673.
[33] Deng X, Zhang X, Li W, et al. Chronic liver injury induces conversion of biliary epithelial cells into hepatocytes[J]. Cell Stem Cell, 2018, 23:114-122.
[34] Español-Suñer R, Carpentier R, Van Hul N, et al. Liver progenitor cells yield functional hepatocytes in response to chronic liver injury in mice[J]. Gastroenterology, 2012, 143:1564-1575.
[35] Mehendale HM. Tissue repair:an important determinant of final outcome of toxicant-induced injury[J]. Toxicol Pathol, 2005, 33:41-51.
[36] Iredale JP. Models of liver fibrosis:exploring the dynamic nature of inflammation and repair in a solid organ[J]. J Clin Invest, 2007, 117:539-548.
[37] Masuda Y. Learning toxicology from carbon tetrachloride-induced hepatotoxicity[J]. Yakugaku Zasshi, 2006, 126:885-899.
[38] Mangipudy RS, Chanda S, Mehendale HM. Tissue repair response as a function of dose in thioacetamide hepatotoxicity[J]. Environ Health Perspect, 1995, 103:260-267.
[39] Rao PS, Mangipudy RS, Mehendale HM. Tissue injury and repair as parallel and opposing responses to CCl4 hepatotoxicity:a novel dose-response[J]. Toxicology, 1997, 118:181-193.
[40] Lai C, Feng T, Wei L, et al. Development and validation of a primate model for liver fibrosis[J]. J Pharmacol Toxicol Methods, 2019, 100:106600.
[41] Woolbright Bl, Jaeschke H. Inflammation and cell death during cholestasis:the evolving role of bile acids[J]. Gene Exp, 2019, 19:215-228.
[42] Santiago P, Scheinberg AR, Levy C. Cholestatic liver diseases:new targets, new therapies[J]. Ther Adv Gastroenterol, 2018, 11:1-15.
[43] Zhang Y, Lu Y, Ji H, et al. Anti-inflammatory, anti-oxidative stress and novel therapeutic targets for cholestatic liver injury[J]. Biosci Trends, 2019, 13:23-31.
[44] Tsay HC, Yuan Q, Balakrishnan A, et al. Hepatocyte-specific suppression of microRNA-221-3p mitigates liver fibrosis[J]. Hepatology, 2019, 70:722-734.
[45] Chang N, Tian L, Ji X, et al. Single-cell transcriptomes reveal characteristic features of mouse hepatocytes with liver cholestatic injury[J]. Cells, 2019, 8:1069-1087.
[46] Graf D, Kohlmann C, Haselow K, et al. Bile acids inhibit interleukin-6 signaling via Gp130 receptor-dependent and -independent pathways in rat liver[J]. Hepatology, 2006, 44:1206-1217.
[47] Preisegger KH, Factor VM, Fuchsbichler A, et al. Atypical ductular proliferation and its inhibition by transforming growth factor beta1 in the 3,5-diethoxycarbonyl-1,4-dihydrocollidine mouse model for chronic alcoholic liver disease[J]. Lab Invest, 1999, 79:103-109.
[48] Carpino G, Nevi L, Overi D, et al. Peribiliary gland niche participates in biliary tree regeneration in mouse and in human primary sclerosing cholangitis[J]. Hepatology, 2019. DOI:10.1002/hep. 30871.
[49] Thomas JA, Pope C, Wojtacha D, et al. Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function[J]. Hepatology, 2011, 53:2003-2015.
[50] Sakaida I, Terai S, Yamamoto N, et al. Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice[J]. Hepatology, 2004, 40:1304-1311.
[51] Meier RP, Mahou R, Morel P, et al. Microencapsulated human mesenchymal stem cells decrease liver fibrosis in mice[J]. Hepatology, 2015, 62:634-641.
[52] Wang L, Wang X, Xie G, et al. Liver sinusoidal endothelial cell progenitor cells promote liver regeneration in rats[J]. J Clin Invest, 2012, 122:1567-1573.
[53] Houlihan DD, Newsome PN. Critical review of clinical trials of bone marrow stem cells in liver disease[J]. Gastroenterology, 2008, 135:438-450.
[54] Bird TG, Lu WY, Boulter L, et al. Bone marrow injection stimulates hepatic ductular reactions in the absence of injury via macrophage-mediated tweak signaling[J]. Proc Natl Acad Sci U S A, 2013, 110:6542-6547.
[55] Fuchs BC, Hoshida Y, Fujii T, et al. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma[J]. Hepatology, 2014, 59:1577-1590.
[56] Puche JE, Lee YA, Jiao J, et al. A novel murine model to deplete hepatic stellate cells uncovers their role in amplifying liver damage in mice[J]. Hepatology, 2013, 57:339-350.
[57] Yin C, Evason KJ, Maher JJ, et al. The basic helix-loop-helix transcription factor, heart and neural crest derivatives expressed transcript 2, marks hepatic stellate cells in zebrafish:analysis of stellate cell entry into the developing liver[J]. Hepatology, 2012, 56:1958-1970.
[58] Schuppan D, Kim YO. Evolving therapies for liver fibrosis[J]. J Clin Invest, 2013, 123:1887-1901.
[59] Manco R, Clerbaux LA, Verhulst S, et al. Reactive cholangiocytes differentiate into proliferative hepatocytes with efficient DNA repair in mice with chronic liver injury[J]. Hepatology, 2019, 70:1180-1191.
[60] Russell JO, Lu WY, Okabe H, et al. Hepatocyte-specific Β-catenin deletion during severe liver injury provokes cholangiocytes to differentiate into hepatocytes[J]. Hepatology, 2019, 69:742-759.
[61] Thakore KN, Mehendale HM. Role of hepatocellular regeneration in CCl4 autoprotection[J]. Toxicol Pathol, 1991, 19:47-58.
[62] Mangipudy RS, Chanda S, Mehendale HM. Hepatocellular regeneration:key to thioacetamide autoprotection[J]. Pharmacol Toxicol, 1995, 77:182-188.
[63] Dalhoff K, Laursen H, Bangert K, et al. Autoprotection in acetaminophen intoxication in rats:the role of liver regeneration[J]. Pharmacol Toxicol, 2001, 88:135-141.
[64] Chanda S, Mangipudy RS, Warbritton A, et al. Stimulated hepatic tissue repair underlies heteroprotection by thioacetamide against acetaminophen-induced lethality[J]. Hepatology, 1995, 21:477-486.
[65] Yannaki E, Athanasiou E, Xagorari A, et al. G-Csf-primed hematopoietic stem cells or G-Csf per se accelerate recovery and improve survival after liver injury, predominantly by promoting endogenous repair programs[J]. Exp Hematol, 2005, 33:108-119.
[66] Piscaglia AC, Shupe TD, Oh SH, et al. Granulocyte-colony stimulating factor promotes liver repair and induces oval cell migration and proliferation in rats[J]. Gastroenterology, 2007, 133:619-631.
[67] Forbes SJ, Newsome PN. Liver regeneration-mechanisms and models to clinical application[J]. Nat Rev Gastroenterol Hepatol, 2016, 13:473-485.
[68] Dai Z, Song G, Balakrishnan A, et al. Growth differentiation factor 11 attenuates liver fibrosis via expansion of liver progenitor cells[J]. Gut, 2019. DOI:10.1136/gutjnl-2019-318812.
[69] Mu X, Español-Suñer R, Mederacke I, et al. Hepatocellular carcinoma originates from hepatocytes and not from the progenitor/biliary compartment[J]. J Clin Invest, 2015, 125:3891-3903.
[70] Zhu M, Lu T, Jia Y, et al. Somatic mutations increase hepatic clonal fitness and regeneration in chronic liver disease[J]. Cell, 2019, 177:608-621.
[71] Sun X, Chuang JC, Kanchwala M, et al. Suppression of the Swi/Snf Component Arid1a promotes mammalian regeneration[J]. Cell Stem Cell, 2016, 18:456-466.
[72] Nanthakumar CB, Hatley RJ, Lemma S, et al. Dissecting fibrosis:therapeutic insights from the small-molecule toolbox[J]. Nat Rev Drug Discov, 2015, 14:693-720.
[73] Maurer B, Stanczyk J, Jüngel A, et al. Microrna-29, a key regulator of collagen expression in systemic sclerosis[J]. Arthritis Rheum, 2010, 62:1733-1743.
[74] Pogribny IP, Starlard-Davenport A, Tryndyak VP, et al. Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice[J]. Lab Invest, 2010, 90:1437-1446.
[75] Chen Y, Verfaillie CM. MicroRNAs:the fine modulators of liver development and function[J]. Liver Int, 2014, 34:976-990.
[76] Pan C, Chen H, Wang L, et al. Down-regulation of miR-127 facilitates hepatocyte proliferation during rat liver regeneration[J]. PLoS One, 2012, 7:e39151.
[77] Psaltis PJ, Simari RD, Rodriguez-Porcel M. Emerging roles for integrated imaging modalities in cardiovascular cell-based therapeutics:a clinical perspective[J]. Eur J Nucl Med Mol Imaging, 2012, 39:165-181.